

Information about proposed Board members prior to the Annual General Meeting 2022

Pål Ryfors

Born 1983

Other assignments

Chief Executive Officer of Episurf Medical AB and Board member of Aros Kapital AB.

Previous experience

Pål has vast experience from leading positions within the finance and banking sector both in the Nordics and internationally. He has previously been CFO of Marginalen Bank and Head of Group Controlling at Hoist Finance AB. Prior to that, he was an investment banker at Societe Generale in London, a position he assumed after holding several leading positions in the restructuring of the Swedish operations of Kaupthing Bank.

Education

Bachelor in Financial Economics from Gothenburg School of Economics.

Independence

Independent in relation to the company and its executive management

Independent in relation to major shareholders of the company

Holdings of shares or other financial instruments in the company (including holdings of related persons)

-

Roger Tell

Born 1965

Other assignments

Chief Scientific Officer and Chief Medical Officer of Isofol Medical AB.

Previous experience

Vice President of Clinical Development at Aprea Therapeutics and International Clinical Project Director at Servier in Suresnes, France. He has an extensive experience as an oncologist as well as an advisor to biopharma companies, including Eli Lilly, Astra Zeneca and Merck Serono.

Education

Medical degree and a doctorate in experimental oncology from the Karolinska Institute in Sweden.

Independence

Independent in relation to the company and its executive management

Independent in relation to major shareholders of the company

Holdings of shares or other financial instruments in the company (including holdings of related persons)

-

Hege Hellström

Born 1965

Member of the Board since September 2019

Member of the Audit Committee

Other assignments

Founder and manager of Belnor BVBA, a consultancy and investment company. She is also a non-executive Board member at Camurus AB (CAMX.ST), a Swedish biotech company, and Advicenne (Euronext: ADVIC), a French pharmaceutical company.

Previous experience

Hege worked at the biotechnology company Sobi from 2013 until 2018 and was president for EMENAR (Europe, Middle East, North Africa and Russia). Prior to that, she was globally responsible for the Cardiovascular business area within Sanofi, VP Renal Europe and Head of Regional Liaisons at Sanofi, VP Renal and Endocrine Europe at Genzyme and General Manager Benelux at Genzyme. Before Genzyme, she was 13 years at Baxter.

Education

Norge B.Sc., Medical Laboratory Scientist, 1985, Oslo Metropolitan University, Norway.

Independence

Independent in relation to the company and its executive management

Independent in relation to major shareholders of the company

Holdings of shares or other financial instruments in the company (including holdings of related persons)

-

Peter Zonabend

Born 1980

Member of the Board since March 2019

Chair of the Audit Committee

Other assignments

CEO Arwidsro, Board assignments within Arwidsro and member of the Board of Hoist Finance AB.

Previous experience

CEO of Victoria Investments Holding Ltd, 2010-2017, Law Firm Fylgia, Law Firm Björn Rosengren. Board assignments within Hövding Sverige AB, HQ AB, TCER AB, CBD Solutions AB.

Education

LL.M from Stockholm University, EMLE from Université Paul Cézanne Aix-Marseille III, Bsc in Business and Economics from Stockholm University and DU EAED from Université Paul Cézanne Aix-Marseille III.

Independence

Independent in relation to the company and its executive management

Not independent in relation to major shareholders of the company

I Holdings of shares or other financial instruments in the company (including holdings of related persons)
600,000 shares. Manages 79,917 shares by proxy.

Notes

The information above refers to the situation at the time of the notice of the Annual General Meeting.